Company profile for Zhejiang Hisun Chemical Co., Ltd.

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Zhejiang Hisun Chemical Co., Ltd (hereafter called as ”Hisun Chemical), founded in 1998, is a state-holding enterprise invested by State Development & Investment Corporation(SDIC), Zhejiang Hisun Group and ZMC Co., Ltd. The company now covers an area of 312,000 square meters and 35% of its staff members are technicians. With its total assets of nearly USD 60 million, Hisun Chemical has created a niche in agrochemical field t...
Zhejiang Hisun Chemical Co., Ltd (hereafter called as ”Hisun Chemical), founded in 1998, is a state-holding enterprise invested by State Development & Investment Corporation(SDIC), Zhejiang Hisun Group and ZMC Co., Ltd. The company now covers an area of 312,000 square meters and 35% of its staff members are technicians. With its total assets of nearly USD 60 million, Hisun Chemical has created a niche in agrochemical field through its sustainable researching, marketing efforts and strong distribution network. The company, with its headquarter located in Taizhou, Zhejiang, now has two wholly-owned subsidiary companies , two Sino-foreign joint ventures and one Provincial Hi-tech R&D Centre. Since it was established, Hisun Chemical has already passed ISO9000 & ISO14000 and gained lots of honors like “First AA-level Credit Enterprise of China Pesticide Industry” and “National Hi-tech Enterprise”, etc. Its product, Abamectin has also gained such awards as ”First Prize of S&T Advance Award of China Chemical Industry”, “Major Achievements in National Technologies R&D Program of the 8th Five-year plan of China” and “ Outstanding Project Award in National Technology Innovation Program of the 8th Five-year of China”. Meanwhile, Hisun Chemical has also undertaken the project of Emamectin Benzoate in National Key Technologies R&D program of the 9th Five-year plan of China. And Ascomycin, a kind of its biofungicides, has been listed in “National S&T Pillar Program of Technical Material Development in the 11th Five-year plan of China.” Based on full implement of EHS system and high quality product, Hisun Chemical has been one of the suppliers to many multinational companies, like Bayer, Syngenta, Boehringer Ingelheim and Cheminova, establishing long term business relationship with them. Hisun Chemical exports 85% of its products, ranging from Insecticides, Herbicides to Fungicides, directly to more than 50 countries over the world. Among those products, its patented products such as Oxine copper 33.5% SC & Flazasulfuron have obtained exclusive registration in China. Hisun Chemical adheres to “For Shareholders, For Staff, For Community” as its management purpose, “Honesty, Innovation, Collaboration& Diligence” as its core values, and “Broad Mind& Integrity” as its spirit. With advanced technology, and R&D, Hisun Chemical will strive to become a representative of Agrochemical, Pharmaceutical &Animal Health Field in the 21st century. Our Group-ZHEJIANG HISUN GROUP The original name of Hisun is HaiMen Pharmaceutical Company founded in 1956 and changed her name at 1997 to Zhejiang Hisun Group. Hisun is located in Taizhou, which is a scenic and coastal city at East Sea in China and is part of the southern tip of Shanghai Economic Zone. It contains 100 hectare area and there are more than 3000 employees. Hisun is ranked in the top 520 key enterprises in China, total asset of Hisun has reached RMB 1.6 billion, there is a national R&D center in Hisun and more than 30% of its staff are technician. Hisun has developed into the largest antibiotic and antineoplastic manufacturer and become a reputed one of main chemical production bases in China. There are three main subsidiary companies under Hisun Group which are Hisun pharmaceutical has been listed in SSE, Hisun Chemical and Hisun thermoelectricity. T products of Hisun have been approved and certified by FDA of U.S.A. meanwhile Hisun have got the approvals of ISO9001, ISO9002 and ISO14000. Hisun exports 80% of its products to approximately 100 countries all over the world, the products performance has been approved by domestic and international consumers.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
No.97 Waisha Road, Jiaojiang District, Taizhou, Zhejiang 318000
Telephone
Telephone
+86 576 88827793
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

CPhI South East Asia

Not Confirmed

envelop Contact Supplier

CPhI South East Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

INTERVIEW #SpeakPharma

[Sponsored by another company]
Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets
With increasing flavour bans in key markets, vaping brands are facing significant challenges in providing satisfying alternatives to vapers and smokers looking to transition. Recognising this need, Alchem NicSelect™ is making a bold move by offering its key customers royalty-free and unrestricted geographical access to its revolutionary T-MAX™ technology.“At Alchem NicSelect™, we understand the urgency for vaping brands to adapt to new regulations without compromising on satisfaction. By offering royalty-free access to T-MAX™ technology, we empower our customers to provide the closest cigarette-like experience possible, even in markets with strict flavour restrictions,” said Riccardo Santambrogio, Europe Sales Manager.HIGHLIGHTS// offering royalty-free access to T-MAX™ technology/ unrestricted geographical access/ closest cigarette-like experience Addressing the biggest barrier: Nicotine satisfactionOne of the primary reasons many vapers are dissatisfied and smokers struggle to switch to vaping is that traditional nicotine solutions fail to replicate the rapid satisfaction provided by cigarettes. Nicotine replacement therapies (NRTs) and even conventional vaping products often lack the immediate nicotine hit, throat feel, and overall experience that smokers are accustomed to. T-MAX™ solves this problem by engineering a nicotine experience that closely mimics cigarette consumption without relying on flavours.T-MAX™ provides a unique 3-in-1 approach:1. The Speed of a Cigarette – Rapid nicotine delivery and rush within seconds for immediate satisfaction.2. The Power of Nicotine Salts – A stronger perceived nicotine effect without exceeding legal limits (20 mg/ml nicotine limit under the European Tobacco Products Directive). With T-MAX™, 8 mg/ml feels like 20 mg/ml, and 14 mg/ml feels like 40 mg/ml.3. The Throat Hit of Freebase Nicotine – Especially in a flavour-free formulation, the combined ingredients in T-MAX™ deliver an even more satisfying throat feel than expected from nicotine base, much closer to and more familiar with a cigarette throat feel that habitual smokers recognise.HIGHLIGHTS// unique 3-in-1 approach/ rush within seconds/ stronger perceived nicotine effect without exceeding legal limits/ more satisfying throat feel that habitual smokers recogniseNo flavour, but not less satisfyingWhile flavours have traditionally played a role in vaping adoption, market realities are shifting. With flavour bans spreading across regions, brands need solutions that deliver satisfaction without relying on taste. Consumer research has shown that T-MAX™ performs exceptionally well even without added flavours. Since most cigarette smokers do not smoke for the tobacco flavour but rather for the nicotine hit and habitual experience, T-MAX™ provides a viable alternative that aligns with new regulatory landscapes.HIGHLIGHTS// flavour bans spreading across regions/ T-MAX™ performs exceptionally well even without added flavoursEmpowering vape brands with free access to T-MAX™By granting customers royalty-free access to the T-MAX™ technology, Alchem NicSelect™ is removing barriers for vaping brands and original equipment manufacturers (OEMs) looking to adapt to regulatory changes. This open-access approach ensures that manufacturers can integrate T-MAX™ into their product lines without additional costs, allowing them to offer superior nicotine satisfaction in markets where flavours are no longer an option.HIGHLIGHTS// removing barriers for vaping brands and OEMs looking to adapt/ manufacturers can integrate T-MAX™ into product lines without additional costsThe future of vaping in restricted marketsWith T-MAX™, the vaping industry has a powerful tool to retain customers and convert smokers who have struggled with traditional vaping products. By delivering the key elements of cigarette satisfaction — without combustion or flavours — T-MAX™ is set to redefine what a satisfying vape experience means in a post-flavour-ban world.“Our commitment to innovation and accessibility means we are providing our customers with the solutions they need to navigate an evolving regulatory landscape. T-MAX™ allows brands to offer a highly satisfying experience that mimics smoking without relying on flavours. The message is clear: no flavour, but not less satisfying”, added Santambrogio.HIGHLIGHTS// powerful tool to retain customers and convert smokers/ delivering the key elements of cigarette satisfaction without combustion or flavours/ no flavour, but not less satisfying

Impressions: 1298

https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets

Radio Compass
06 May 2025

VLOG #PharmaReel

[Sponsored by another company]
This PharmaReel highlights Gentec Pharmaceutical's expertise in generic APIs, HPAPIs, and prostaglandins with more than 30 years of experience. Operating from EU-GMP-certified facilities, the company exports to over 70 countries worldwide.

Impressions: 179

read-more

DATA COMPILATION #PharmaFlow

[Sponsored by another company]
CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint
During the second quarter (Q2) of 2025, contract development and manufacturing organizations (CDMOs) made substantial investments in specialized therapeutic manufacturing. The quarter also saw CDMOs pursue high-value, complex manufacturing niches, particularly in antibody-drug conjugates (ADCs), cell and gene therapies (CGTs) and oligonucleotides.Alongside these trends, Q2 also saw CDMOs strengthen their footprint in the United States amid concerns over rising tariffs and unpredictable trade policies being enforced by the Trump administration.Regeneron Pharmaceuticals committed over US$ 3 billion through a 10-year agreement with Fujifilm Diosynth Biotechnologies to nearly double its US manufacturing capacity for biologics. Under this agreement, Fujifilm will manufacture and supply drug products for Regeneron at its large-scale facility in Holly Springs, North Carolina.Thermo Fisher Scientific announced plans to invest an additional US$ 2 billion in the US over four years, reinforcing its manufacturing and R&D capabilities. With 64 facilities spread across 37 states, Thermo Fisher aims to bolster American innovation and competitiveness. Similarly, Piramal Pharma announced a US$ 90 million investment plan for expanding two facilities in the US, thereby bringing its total investment in the country to US$ 570 million. View CDMO Activity Tracker for Q2 2025 (Free Excel Available)Veranova, Carbogen lead ADC wave; Axplora doubles down on HPAPI production in ItalyThe quarter saw substantial investments in ADC manufacturing. Veranova announced a US$ 20 million investment in bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts campus. With this investment, Veranova will be able to provide a more comprehensive suite of services to its partners developing ADCs and other bioconjugates. Veranova’s total investment in the Devens facility now stands at over US$ 50 million. Swiss CDMO Carbogen announced a US$ 31 million co-investment with an unnamed Japanese investor to expand its capabilities across its Aarau and Neuland (Switzerland) facilities. The facility will address increasing demand for complex and high-value compounds such as ADC drug linkers.Axplora announced a further €35 million (US$ 41 million) expansion of its Farmabios site in Italy, doubling the facility to approximately 108,000 square meters by mid-2026. This investment raises its total spend on the site to over €80 million (US$ 94.05 million) since 2019, supporting the production of highly potent active pharmaceutical ingredients (HPAPIs). Farmabios now stands as a key hub in Axplora’s global CDMO network.Polish pharmaceutical manufacturer Polfa Tarchomin is positioning itself as a significant player in the European CDMO market through its investment in the Center for Development and Production of Highly Potent Drugs. This 12,000 square meter facility has two state-of-the-art production lines designed for filling vials and pre-filled syringes with an annual capacity of 26 million product units.Skyepharma’s projected annual revenues from oncology-linked activities touched €10 million (US$ 11.2 million). The CDMO’s facility in Saint-Quentin-Fallavier is equipped to handle cytotoxic and cytostatic compounds, and is one of the few facilities in France capable of managing HPAPIs for oral anticancer treatments. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Athena acquires Medipha Santé, Famar buys MiP Pharma’s German site to strengthen European footprintDuring the quarter, several CDMOs enhanced their strategic capabilities through M&As. Athena Pharmaceutiques acquired  Medipha Santé to build a fully integrated pharmaceutical services platform in Europe. Based in Paris, Athena has strengthened its commercial and regulatory toolbox by bringing aboard Medipha Santé’s 35-strong team, which supports over 100 partner organizations and files approximately 350 dossiers annually with ANSM and other European agencies. With this integration, Athena positions itself as a one-stop CDMO partner.With the acquisition of MiP Pharma’s sterile manufacturing site in Homburg, Germany, the Famar Group has expanded its capabilities in aseptic and lyophilized fill-and-finish operations. The acquisition has strengthened Famar’s position in sterile drug manufacturing. The CDMO now has seven manufacturing facilities in Europe.PCI Pharma Services’ acquisition of Ajinomoto Althea has established a world-class, large-scale manufacturing hub in the San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high-potent formulations such as ADCs. PCI Pharma is now amongst the few US-based CDMOs capable of comprehensive ADC manufacturing.Samsung Biologics’ strategic spinoff of its biosimilar business stood out as a significant corporate restructuring exercise during the quarter. The separation of Samsung Bioepis, tentatively renamed Samsung Epis Holdings, aims to enhance Samsung Biologics’ strategic focus and build client trust, as it eliminates potential conflicts between CDMO services and proprietary drug development. The move came after Samsung Biologics inked a contract worth 737.3 billion Korean won (US$ 518 million) with an undisclosed US pharmaceutical company.WuXi Biologics announced a US$ 167 million divestment of its German facility to Terumo and broke ground on a microbial production plant in China. National Resilience, which was launched five years ago as the US drug manufacturer dedicated to broadening access to medicines and protecting biopharma supply chains, said it is shuttering six of its 10 facilities. The company said the sites were “not being fully utilized.” View CDMO Activity Tracker for Q2 2025 (Free Excel Available) MilliporeSigma, Simtra form 5-year ADC alliance; Silexion partners Catalent for siRNA developmentMerck KGaA’s MilliporeSigma and Simtra struck a five-year strategic alliance, combining expertise across the ADC value chain to reduce development timelines and complexity for biopharmaceutical companies. Viralgen collaborated with Trogenix to rapidly scale product supply for TGX-007, an AAV gene therapy for glioblastoma (a type of cancer of the brain and spinal cord).  Silexion announced a collaboration with Catalent for small interfacing RNA (siRNA) development and manufacturing. Catalent’s Limoges (France) facility will conduct formulation development and clinical manufacturing for Silexion’s SIL204 candidate, supporting both systemic and intra-tumoral delivery formulations.Skyepharma’s collaboration with Eneapharm through the Skyehub platform aims to support the treatment of patients suffering from exocrine pancreatic insufficiency, including those affected by cystic fibrosis or pancreatic cancer. Orion Corporation reached an agreement with Shilpa Biocare for the distribution of recombinant human albumin in Europe.Meanwhile, Aenova announced the launch of its Aenovation program, an initiative designed to fast-track early development of pharmaceutical formulations. The program addresses the critical challenges of bioavailability and time-to-market faced by poorly soluble drug candidates. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Our view The quarter saw CDMO developments mimic the broader trends in the pharmaceutical industry, such as onshoring of critical manufacturing capabilities in the US, consolidation of specialized expertise through strategic partnerships, and the relentless focus on emerging therapeutic modalities that promise to transform patient care. With CDMOs continuing to invest in next-generation manufacturing capabilities, we expect the sector to play a crucial role in drug innovation. 

Impressions: 341

https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint

#PharmaFlow by PHARMACOMPASS
10 Jul 2025

NEWS #PharmaBuzz

read-more
read-more

http://www.fiercepharma.com/manufacturing/china-s-troubled-zhejiang-hisun-keeps-picks-up-new-u-s-business

Eric Palmer FIERCE PHARMA
11 Aug 2016

ABOUT THIS PAGE

Contact Zhejiang Hisun Chemical Co., Ltd. and get a quotation

Zhejiang Hisun Chemical Co., Ltd. is a supplier offers 74 products (APIs, Excipients or Intermediates).

Find a price of 31139-87-4 bulk with JDMF offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of 4-Biphenylacetic Acid bulk with JDMF offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Biotin bulk with JDMF offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Bisbentiamine bulk with JDMF offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Candesartan Cilexetil bulk with JDMF offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Escitalopram Oxalate bulk with JDMF offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Polaprezinc bulk with JDMF offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Procainamide Hydrochloride bulk with JDMF offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Acarbose bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Ademetionine 1,4-Butanedisulfonate bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Ademetionine Disulfate Tosylate bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Adenosine bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Anastrozole bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Apixaban bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Apremilast bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Aripiprazole bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Bedaquiline bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Bicalutamide bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Bleomycin Sulphate bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Cladribine bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Cyclophosphamide bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Cytarabine bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Dactinomycin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Daptomycin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Daunorubicin HCl bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Donepezil bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Doxorubicin Hydrochloride bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Eltrombopag bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Emodepside bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Epirubicin Hydrochloride bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Eprinomectin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Everolimus bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Fipronil bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Fludarabine Phosphate bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Fluralaner bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Fluvastatin Sodium bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Glucosamine Sulfate Sodium Chloride bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Glutathione bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Idarubicin Hydrochloride bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Imidacloprid bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Imipenem + Cilastatin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Immunomycin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Isepamicin Sulfate bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Ivermectin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Letrozole bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Linezolid bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Lovastatin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Lurasidone Hydrochloride bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Meropenem bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Mesna bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Methoprene bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Micafungin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Milbemycin Oxime bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Minocycline Hydrochloride bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Mitomycin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Moxidectin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Mycophenolate Mofetil bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Mycophenolic Acid bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Orlistat bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Oseltamivir Phosphate bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Pirarubicin HCl bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Pravastatin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Praziquantel bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Pyrroloquinoline Quinone Disodium bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Rifamycin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Selamectin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Simvastatin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Sirolimus bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Tacrolimus bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Tazobactam Sodium bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Teicoplanin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Ticagrelor bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Tigecycline bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Find a price of Tulathromycin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty